Core Scientific, Inc./tx (NASDAQ: CORZ) reported an insider sale on April 13, 2026, when Chief Legal and Administrative Officer Todd Duchene disposed of 10,000 shares of common stock, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The disposition took place under a Rule 10b5-1 trading plan that Duchene established on December 5, 2025. The sale was carried out in two separate transactions. In the first, 9,600 shares were sold at a weighted average price of $18.6094, producing $178,650 in proceeds; the execution prices for those shares ranged between $17.94 and $18.90. The second transaction covered 400 shares, sold at a weighted average price of $18.9925 for proceeds of $7,597, with execution prices ranging from $18.97 to $19.04. The combined value of the two transactions amounted to $186,247.
Following the April 13 transactions, Duchene directly holds 2,027,089 shares of Core Scientific common stock.
The company's share price is trading at $19.06, representing a 173% gain over the past year. According to InvestingPro analysis, Core Scientific appears overvalued at current levels and is listed on the platform's Most Overvalued list; the analysis also flags the stock's high volatility as one of the 10+ key insights included in its Pro Research Report for CORZ.
On the financing front, Core Scientific has secured an additional $500 million credit facility from JPMorgan Chase Bank, increasing total commitments under that facility to $1 billion. This arrangement follows a prior $500 million loan facility closed with Morgan Stanley, which includes an accordion feature that allows for further expansion of commitments. Borrowings under these facilities carry interest indexed to the Secured Overnight Financing Rate plus 250 basis points.
Analysts have been active in response to the company's recent updates. Citizens reiterated a Market Outperform rating and maintained a $30 price target after adjusting estimates following Core Scientific's fourth-quarter fiscal 2025 results. Canaccord raised its price target to $20 while keeping a Buy rating, citing the acquisition of a new site in Texas and power capacity expansions in both Georgia and Texas as influencing factors. Needham moved its rating to Buy from Hold and set a $23 price target, reflecting the stock's current valuation and anticipated lease agreements.
These financing moves, site acquisitions and capacity increases have prompted a period of notable corporate activity for Core Scientific, combining insider trading, capital structure changes and analyst reassessments. The company's additional credit commitments and the accordion feature in the Morgan Stanley facility provide flexibility in funding, while analyst commentary reflects differing views on valuation and growth prospects tied to site and power expansion plans.
Investors and market observers should note the precise terms and timing of Duchene's sale - executed under an established Rule 10b5-1 plan - and the juxtaposition of insider selling with fresh external financing and bullish analyst actions. The mix of these developments frames the near-term corporate and market narrative for CORZ.